Search Results - "Devriese, Lot A"

The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis by de Ruiter, Emma J., Ooft, Marc L., Devriese, Lot A., Willems, Stefan M.

“…Background - The presence of tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment is associated with an improved prognosis and a better response…”
Get full text

The prognostic role of NK cells and their ligands in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis by Bisheshar, Sangeeta K., De Ruiter, Emma J., Devriese, Lot A., Willems, Stefan M.

“…Background : Despite the improvement in therapeutic interventions, 5-year survival rates in Head and Neck Squamous Cell Carcinoma (HNSCC) are limited. HNSCC is…”
Get full text

Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial by Ferris, Robert L, Spanos, William C, Leidner, Rom, Gonçalves, Anthony, Martens, Uwe M, Kyi, Chrisann, Sharfman, William, Chung, Christine H, Devriese, Lot A, Gauthier, Helene, Chiosea, Simon I, Vujanovic, Lazar, Taube, Janis M, Stein, Julie E, Li, Jun, Li, Bin, Chen, Tian, Barrows, Adam, Topalian, Suzanne L

“…BackgroundHead and neck squamous cell carcinomas (HNSCCs) are common malignancies caused by carcinogens, including tobacco and alcohol, or infection with human…”
Get full text

Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol by Schaeffers, Anouk W. M. A, Devriese, Lot A, van Gils, Carla H, Dankbaar, Jan Willem, Voortman, Jens, de Boer, Jan Paul, Slingerland, Marije, Hendriks, Mathijs P, Smid, Ernst J, Frederix, Geert W. J, de Bree, Remco

“…Chemoradiotherapy with cisplatin in a triweekly regimen of 100 mg/m2 body surface area, is used to treat locally advanced head and neck squamous cell carcinoma…”
Get full text

Sinonasal Squamous Cell Carcinoma in the Netherlands: A Population-Based Study of 568 Cases Diagnosed in 2008-2021 by van de Velde, Lise J, Scheurleer, W F Julius, Braunius, W Weibel, Speksnijder, Caroline M, de Ridder, Mischa, Devriese, Lot A, de Bree, Remco, Breimer, Gerben E, Rijken, Johannes A, van Dijk, Boukje A C

“…Sinonasal squamous cell carcinoma is known for its rarity and poor prognosis. This study aims to investigate the trends in the incidence of sinonasal squamous…”
Get full text

Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer by Chargi, Najiba, Bashiri, Fereshta, Wendrich, Anne W., Smid, Ernst J., de Jong, Pim A., Huitema, Alwin D. R., Devriese, Lot. A., de Bree, Remco

“…Purpose Evidence suggests that patients’ skeletal muscle mass (SMM) can predict the patients at risk for cisplatin dose-limiting toxicities (DLT). Cisplatin is…”
Get full text

The association between skeletal muscle measures and chemotherapy‐induced toxicity in non‐small cell lung cancer patients by Jong, Corine, Chargi, Najiba, Herder, Gerarda J.M., Haarlem, Simone W.A., Meer, Femke, Lindert, Anne S.R., Heuvel, Alexandra, Brouwer, Jan, Jong, Pim A., Devriese, Lot A., Huitema, Alwin D.R., Egberts, Toine C.G., Bree, Remco, Deneer, Vera H.M.

“…Background Chemotherapy‐induced toxicities frequently occur in non‐small cell lung cancer (NSCLC) patients treated with platinum‐based chemotherapy. Low…”
Get full text

Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors by van de Geer, Wesley S., Mathijssen, Ron H.J., van Riet, Job, Steeghs, Neeltje, Labots, Mariette, van Herpen, Carla, Devriese, Lot A., Tjan-Heijnen, Vivianne C.G., Voest, Emile E., Sleijfer, Stefan, Martens, John W.M., Cuppen, Edwin, van de Werken, Harmen J.G., Bins, Sander

“…Drug resistance is a perpetual problem in cancer therapy with many underlying mechanisms. Alterations in drug transport over the cancer cell membrane can…”
Get full text

Accurate detection of circulating tumor DNA using nanopore consensus sequencing by Marcozzi, Alessio, Jager, Myrthe, Elferink, Martin, Straver, Roy, van Ginkel, Joost H., Peltenburg, Boris, Chen, Li-Ting, Renkens, Ivo, van Kuik, Joyce, Terhaard, Chris, de Bree, Remco, Devriese, Lot A., Willems, Stefan M., Kloosterman, Wigard P., de Ridder, Jeroen

“…Levels of circulating tumor DNA (ctDNA) in liquid biopsies may serve as a sensitive biomarker for real-time, minimally-invasive tumor diagnostics and…”
Get full text

Diagnostic and Treatment-Related Challenges in Sinonasal Teratocarcinosarcoma: A Report of Three Cases by Scheurleer, W. F. Julius, Braunius, Weibel W., Tijink, Bernard M., Janssen, Luuk M., Pameijer, Frank A., Breimer, Gerben E., Smid, Ernst J., de Bree, Remco, Devriese, Lot A., Rijken, Johannes A.

“…Background. Sinonasal teratocarcinosarcoma is a rare, aggressive malignancy located almost exclusively in the nasal cavity, paranasal sinuses, or anterior…”
Get full text

Author Correction: Accurate detection of circulating tumor DNA using nanopore consensus sequencing by Marcozzi, Alessio, Jager, Myrthe, Elferink, Martin, Straver, Roy, van Ginkel, Joost H., Peltenburg, Boris, Chen, Li-Ting, Renkens, Ivo, van Kuik, Joyce, Terhaard, Chris, de Bree, Remco, Devriese, Lot A., Willems, Stefan M., Kloosterman, Wigard P., de Ridder, Jeroen

Get full text

First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer by Klein Nulent, Thomas J. W., van Es, Robert J. J., Willems, Stefan M., Braat, Arthur. J. A. T., Devriese, Lot A., de Bree, Remco, de Keizer, Bart

“…Background Advanced salivary gland cancers become difficult to treat when they are technically irresectable and radiotherapy limits are exceeded. There is also…”
Get full text

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study by Vermunt, Marit A. C., Robbrecht, Debbie G. J., Devriese, Lot A., Janssen, Julie M., Thijssen, Bas, Keessen, Marianne, Eijk, Maarten, Kessels, Rob, Eskens, Ferry A. L. M., Beijnen, Jos H., Mehra, Niven, Bergman, Andries M.

“…Background ModraDoc006 is an oral formulation of docetaxel, which is co‐administered with the cytochrome P450 3A4 and P‐glycoprotein inhibitor ritonavir (r):…”
Get full text

Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial by Topalian, Suzanne L, Bhatia, Shailender, Amin, Asim, Kudchadkar, Ragini R, Sharfman, William H, Lebbé, Celeste, Delord, Jean-Pierre, Dunn, Lara A, Shinohara, Michi M, Kulikauskas, Rima, Chung, Christine H, Martens, Uwe M, Ferris, Robert L, Stein, Julie E, Engle, Elizabeth L, Devriese, Lot A, Lao, Christopher D, Gu, Junchen, Li, Bin, Chen, Tian, Barrows, Adam, Horvath, Andrea, Taube, Janis M, Nghiem, Paul

“…Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer commonly driven by the Merkel cell polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed…”
Get full text

Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC) by de Ruiter, Emma J., Mulder, Frans J., Koomen, Bregje M., Speel, Ernst-Jan, van den Hout, Mari F. C.M., de Roest, Reinout H., Bloemena, Elisabeth, Devriese, Lot A., Willems, Stefan M.

“…Expression of programmed cell death-ligand 1 (PD-L1) is being used as predictive biomarker for immunotherapy in head and neck squamous cell carcinoma (HNSCC)…”
Get full text

The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: The prospective PLATISMA study by Chargi, Najiba, Molenaar-Kuijsten, Laura, Huiskamp, Laura F.J., Devriese, Lot A., de Bree, Remco, Huitema, Alwin D.R.

“…Locally advanced head and neck squamous cell carcinoma (HNSCC) is commonly treated with cisplatin-based chemoradiotherapy (CRT). Cisplatin is associated with…”
Get full text

The association of pretreatment low skeletal muscle mass with chemotherapy dose‐limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high‐dose cisplatin by Bril, Sandra I., Al‐Mamgani, Abrahim, Chargi, Najiba, Remeijer, Peter, Devriese, Lot A., Boer, Jan Paul, Bree, Remco

“…Background Low skeletal muscle mass (SMM) is an adverse prognostic factor for chemotherapy dose‐limiting toxicity (CDLT). In patients with locally advanced…”
Get full text

Metachronous malignancies after response to checkpoint inhibition by de Visser, Mirjam A., Verschaeve, Francois B., Devriese, Lot A., Neyns, Bart, Suijkerbuijk, Karijn P.M.

Get full text

Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial by Oaknin, Ana, Moore, Kathleen, Meyer, Tim, López-Picazo González, José, Devriese, Lot A, Amin, Asim, Lao, Christopher D, Boni, Valentina, Sharfman, William H, Park, Jong Chul, Tahara, Makoto, Topalian, Suzanne L, Magallanes, Manuel, Molina Alavez, Alejandro, Khan, Tariq Aziz, Copigneaux, Catherine, Lee, Michelle, Garnett-Benson, Charlie, Wang, Xuya, Naumann, R Wendel

“…In preliminary findings from the recurrent or metastatic cervical cancer cohort of CheckMate 358, nivolumab showed durable anti-tumour responses, and the…”
Get full text

Differences in the association of time to treatment initiation and survival according to various head and neck cancer sites in a nationwide cohort by Frank, Michaël H., van Dijk, Boukje A.C., Schoonbeek, Rosanne C., Zindler, Jaap, Devriese, Lot A., van Es, Robert J.J., Merkx, Matthias A.W., de Bree, Remco

“…•The relation between Time to Treatment Initiation (TTI) and overall survival was confirmed with variation among different sites.•Advanced stage oral cavity…”
Get full text